Subcutaneous vs IV Infusion: Which Delivery Route Is Right for Your Therapy?

May 4, 2026

This is a subtitle for your new post

When IV therapy is prescribed, most patients assume medication is delivered the same way every time,through a vein via an IV catheter. In reality, several specialty therapies can be administered through two distinct routes: intravenous (IV) or subcutaneous (sub-Q). Understanding the difference between these delivery methods helps patients and caregivers prepare for treatment and ask better questions of their care team.

Pharmko provides both IV and subcutaneous therapies as part of our home infusion services, and our clinical team guides every patient through the right approach for their specific prescription.


What Is Intravenous (IV) Infusion?


Intravenous infusion delivers medication directly into the bloodstream through a vein. This is typically done via a peripheral IV line, a PICC line, or a central venous catheter, depending on the therapy, the patient's vascular access, and the duration of treatment.

IV infusion is used when:

  • The medication requires rapid, complete absorption into the bloodstream
  • The dose is too large or the formulation too concentrated for subcutaneous delivery
  • The therapy must run over a specific, controlled time window (2–8 hours)
  • Frequent or ongoing IV access is already in place

Common IV therapies include IV antibiotics, IVIG (intravenous immunoglobulin), TPN, Remicade, and Milrinone.


What Is Subcutaneous (Sub-Q) Infusion?


Subcutaneous infusion delivers medication into the tissue just beneath the skin,not into a vein. A small needle or soft cannula is inserted at an angle, typically in the abdomen, thigh, or upper arm, and medication is infused slowly over a shorter or longer period depending on the therapy.

Sub-Q delivery is used when:

  • The medication is formulated for subcutaneous absorption
  • The patient benefits from more frequent, smaller-volume doses
  • Vascular access is difficult or limited
  • The patient or caregiver can be trained for independent self-administration


SCIG vs IVIG: The Most Common Subcutaneous Option


The most widely used subcutaneous infusion therapy in home settings is subcutaneous immunoglobulin (SCIG),an alternative to intravenous immunoglobulin (IVIG) for patients with primary immune deficiencies and certain neurological conditions.

Key differences between SCIG and IVIG:

  • Frequency: SCIG is typically given weekly or biweekly in smaller doses; IVIG is given every 3–4 weeks in larger doses
  • Administration site: SCIG uses subcutaneous tissue; IVIG uses venous access
  • Setting: SCIG is often self-administered at home after training; IVIG typically requires a nurse present for the infusion
  • Side effect profile: SCIG is associated with fewer systemic reactions than IVIG, though local site reactions (redness, swelling) are more common

Your immunologist or neurologist will determine which route is appropriate based on your diagnosis, antibody levels, lifestyle, and vascular access. Not all patients are candidates for SCIG.


Which Route Is Right for Your Therapy?


The choice between IV and subcutaneous delivery is determined by the medication itself, not patient preference alone. Most specialty medications are formulated for a specific route,you cannot substitute subcutaneous delivery for IV administration unless your prescribing physician and pharmacist confirm the medication is approved for both.

Factors your care team will consider:

  • The specific drug and its approved administration routes
  • Your diagnosis and clinical goals
  • Your vascular access history and current access options
  • Your ability to self-administer or the availability of caregiver support
  • Your insurance coverage and prior authorization requirements

What to Expect at Home


Whether your therapy is IV or subcutaneous, Pharmko provides full clinical support from first dose through the end of treatment. Our nurses train patients and caregivers on proper technique, site care, and what to watch for. Know which symptoms should prompt a call regardless of your delivery route,reactions can occur with both IV and sub-Q therapies.

Insurance coverage for subcutaneous therapies varies by plan and diagnosis. Pharmko's team handles prior authorization and coordinates coverage verification before your first delivery.



Contact Pharmko to discuss your therapy options: 1-877-540-2003


Home Infusion Therapy in New York
June 17, 2026
Pharmko is based in New York and provides home infusion therapy statewide — IV antibiotics, IVIG, TPN, IDPN, and specialty medications. Licensed, ACHC accredited, and available 24/7.
Home Infusion for Osteomyelitis
June 15, 2026
Osteomyelitis requires weeks of IV antibiotics that can often be completed at home. Learn who qualifies for OPAT, what the treatment timeline looks like, and how Pharmko supports bone infection recovery.
What Is a PICC Line
June 15, 2026
Learn what a PICC line is, how it's inserted, how to care for it at home, and why it's the most common IV access device for home infusion therapy. Pharmko nurses provide full PICC line training.
IV Iron Infusion at Home: Feraheme, Injectafer, and Iron Deficiency Anemia Treatment
June 12, 2026
Learn how IV iron infusion works at home — which products are used, who qualifies, what to expect during treatment, and how Pharmko delivers iron infusion therapy across 22+ states.
Home Infusion for Multiple Sclerosis
June 11, 2026
Learn how home infusion therapy works for multiple sclerosis, including Ocrevus and Tysabri, who qualifies for home-based MS infusions, what to expect, and how Pharmko coordinates care.
TPN at Home: Who Qualifies, How It Works, and What to Expect
June 11, 2026
Learn how total parenteral nutrition (TPN) at home works — who qualifies, how it's delivered, what daily life looks like, and how Pharmko supports patients from first dose through long-term therapy.
Low Albumin in Dialysis Patients
June 3, 2026
Low albumin is a key marker of malnutrition in dialysis patients. Learn what causes albumin decline, when IDPN is indicated, and how Pharmko supports renal nutrition across 22+ states.
Home Infusion Pump Types
June 2, 2026
Learn about the different types of infusion pumps used in home therapy, ambulatory, electronic, elastomeric, and CADD pumps, and how your pump is matched to your specific treatment.
Home Infusion for Rheumatoid Arthritis
May 30, 2026
Learn how home infusion therapy works for rheumatoid arthritis — including Remicade (infliximab) and other IV biologics, who qualifies for home treatment, and how Pharmko supports ongoing RA care.
Sterile Compounding Safety
May 26, 2026
When a patient or provider chooses a compounding pharmacy to prepare IV medications, they are trusting that the pharmacy operates under rigorous, independently enforced standards. In the United States, those standards are defined by two chapters of the United States Pharmacopeia: USP <797> for sterile compounding and USP <800> for hazardous drug handling. Pharmko operates in full compliance with both chapters. Understanding what these standards require, and what happens when they are not met, helps patients and providers make informed decisions about which pharmacy they trust with their care. What Is USP <797>? USP <797> (Pharmaceutical Compounding, Sterile Preparations) is the national standard that defines the minimum requirements for compounding sterile preparations safely. It covers: Cleanroom environment classification, ISO Class 5 at the point of compounding, ISO Class 7 for the surrounding buffer area, ISO Class 8 for the ante-room Personnel training, gowning, and aseptic technique requirements Sterilization and filtration methods by product type Beyond-use dating (BUD), how long a compounded sterile preparation remains safe to use Environmental and personnel monitoring schedules Quality assurance, documentation, and deviation management USP <797> applies to every pharmacy that prepares IV solutions, injections, eye drops, or other sterile preparations, whether they are a hospital pharmacy, ambulatory infusion center, or specialty pharmacy like Pharmko. The 2023 Revision: What Changed USP <797> was significantly revised in 2023 (effective November 2023). Key changes include: Stricter beyond-use date requirements, compounded sterile preparations must now meet more conservative dating limits unless sterility testing supports extended dating Enhanced environmental monitoring, more frequent air and surface sampling with defined action levels Clearer personnel qualification requirements, competency assessments are now required at defined intervals New category system, preparations are now categorized (Category 1 and Category 2) based on sterility assurance level and BUD Pharmacies that were compliant under the previous version of USP <797> must have updated their procedures and infrastructure to meet the 2023 revision. Pharmko updated our facilities, policies, and documentation systems in alignment with the revised chapter. What Is USP <800>? USP <800> (Pharmaceutical Compounding, Hazardous Drugs) establishes standards for the safe handling of hazardous drugs throughout the pharmacy, from receipt and storage to preparation, dispensing, and waste disposal. Hazardous drugs include certain chemotherapy agents, antiviral medications, hormones, and other drugs that pose risks of carcinogenicity, reproductive toxicity, or organ damage at low exposure levels. USP <800> requires: Negative-pressure ventilated containment primary engineering controls (C-PECs) for hazardous drug compounding Separate, dedicated hazardous drug storage areas Personal protective equipment (PPE) requirements for all staff handling hazardous drugs Closed-system drug transfer devices (CSTDs) for certain preparations Spill kits and exposure management protocols Why These Standards Matter for Patients The consequences of non-compliance are serious. High-profile compounding pharmacy failures, including a 2012 fungal meningitis outbreak linked to contaminated steroid injections that killed 64 patients and injured hundreds, demonstrated what happens when sterile compounding standards are not followed. For patients receiving home IV therapy, USP <797> compliance is not a credential to check once and forget, it reflects the ongoing daily practices of the pharmacy preparing their medications. Patients and providers should verify that any pharmacy preparing their IV solutions is accredited, state-licensed, and actively compliant with current USP standards. How Pharmko Meets These Standards Pharmko's sterile compounding facility is designed, staffed, and operated to meet USP <797> and USP <800> requirements. We are ACHC accredited, state-licensed in 22+ states, and subject to regulatory inspection. Every batch we compound is reviewed by a licensed pharmacist, and our environmental and personnel monitoring data is reviewed on a defined schedule. For a broader overview of what sterile compounding is and how it differs from retail pharmacy, see our guide on what is sterile compounding for IV therapy . For providers interested in our compounding capabilities, see our physician services page or contact our pharmacy team directly. → Contact Pharmko about sterile compounding: 1-877-540-2003
Show More